Cortexyme, Inc. is a biopharmaceutical company focused on developing therapeutics for Alzheimer's disease and other degenerative disorders. The company's lead candidate, COR388, targets a specific bacterial infection associated with the development of Alzheimer's disease. Cortexyme is pioneering the field of pathogen-targeted therapeutics, with the goal of addressing the root cause of neurodegenerative disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

9 Patents

#110 in South San Francisco, CA

#7,751 in California

#32,627 in US

South San Francisco, CA, United States of America

Cortexyme, Inc.

Forward Citations = 26

7 inventors:

Casey Crawford Lynch (9 out of 10 patents)

Andrei William Konradi (9 out of 88 patents)

Stephen S Dominy (8 out of 9 patents)

4. Craig Alan Coburn (6 out of 58 patents)

5. Joseph P Vacca (6 out of 110 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cortexyme, Inc.. Retrieved from https://idiyas.com/company/cortexyme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]